Fast Helical Tomotherapy in a head and neck cancer planning study: is time priceless? by Dirk Van Gestel et al.
RESEARCH Open Access
Fast Helical Tomotherapy in a head and
neck cancer planning study: is time
priceless?
Dirk Van Gestel1,2*, Geert De Kerf1,3, Kristien Wouters4, Wouter Crijns5, Jan B. Vermorken6,7, Vincent Gregoire8
and Dirk Verellen9
Abstract
Background: The last few years, in radiotherapy there has been a growing focus on speed of treatment delivery
(largely driven by economical and commercial interests). This study investigates the influence of treatment time on
plan quality for helical tomotherapy (HT), using delivery times with Volumetric Modulated Arc Therapy (VMAT; Rapid
Arc [RA]) as reference.
Methods: In a previous study, double arc RA (Eclipse) and standard HT plans (TomoHD™) were created for five
oropharyngeal cancer patients and reported according to ICRU 83 guidelines. By modifying the beam width from
2.5 to 5.0 cm, elevating the pitch and lowering the modulation factor, “TomoFast” (TF) plans were generated with
treatment times equal to RA plans. To quantify the impact of TF’s craniocaudal gradient, similar plans were
generated on TomoEdgeTM (TomoEdgeFast;TEF). The homogeneity index (HI), conformity index (CI), mean dose,
Dnear-max (D2) and Dnear-min (D98) of the PTVs were analyzed as well as the mean dose, specific critical doses and
volumes of 26 organs at risk (OARs). Data were analyzed using repeated measures ANOVA.
Results: With a mean treatment time of 3.05 min (RA), 2.89 min (TF) and 2.95 min (TEF), PTVtherapeutic coverage was
more homogeneous with TF (HI.07;SE.01) and TEF (HI.08;SE.01) compared to RA (HI.10;SE.01), while PTVprophylactic was
most homogeneous with RA. Mean doses to parotid glands were comparable for RA, TF, TEF: 25.62, 25.34, 23.09 Gy
for contralateral and 32.02, 31.96, 30.01 Gy for ipsilateral glands, respectively. OARs’ mean doses varied between
different approaches not favoring a particular technique. TF’s higher dose to OARs at the cranial-caudal edges of
the PTVs and its higher integral dose, both due to the extended cranial-caudal gradient, seems to be solved by the
new TomoEdge™ software. However, all these faster techniques lose part of standard TomoHD’s OAR sparing
capacity
Conclusion: It is possible to treat oropharyngeal cancer patients using HT (TF/TEF) within time-frames observed for
RA maintaining comparable target coverage and sparing of OARs. This study indicates that treatment time is not
technology specific, rather an operator’s decision on balancing efficiency and quality.
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Background
The last few years rotational Intensity-Modulated
Radiotherapy (IMRT) techniques have become more
popular. They are gradually replacing the older static
beam IMRT techniques mainly based on faster fraction
delivery with at least equal, and often better, sparing of
the organs at risk (OARs) [1]. In a previous planning
study on oropharyngeal cancer we showed the potential
of helical tomotherapy (HT; Accuray, Sunnyvale, CA)
compared to the ‘cone beam’ or ‘volumetric’ rotational
IMRT techniques such as RapidArc (RA; Varian, Palo
Alto, CA) planned with Eclipse (Varian, Palo Alto, CA)
and Elekta VMAT (Elekta, Stockholm, Sweden) planned
with Pinnacle’s SmartArc (Philips, Eindhoven, The
Netherlands) in terms of sparing of the OARs of the
neck [2]. However, treatment time with standard HT
was nearly twice that of RapidArc planned by Eclipse
(3.05 vs 5.94 min). Next to a negative impact on patient
comfort, treatment accuracy (more intrafractional mo-
tion, i.e. motion during one fraction) and department
economics, this longer treatment time potentially may
also have a negative effect on tumor control. Of interest
in this respect is a nasopharyngeal carcinoma cell cul-
ture experiment by Zheng et al. showing longer fraction
delivery times to give less tumor cell kill, probably due
to sub-lethal damage repair during the radiotherapy
session [3]. However, that study compared delivery
times of 15 and 50 min and it is not sure whether their
results are also applicable on delivery times between 3
and 6 min. On the other hand, although the total treat-
ment time is clearly longer with HT than with RA, the
treatment time of a single point (tumor cell) within the
target volume is much shorter and can be as low as
42 s at maximum gantry speed (12 s per gantry rota-
tion), for a standard pitch of .287 [4]. This faster local
dose delivery might result in less sub-lethal damage re-
pair and therefore more lethal damage during a single
treatment session. Shaikh et al. estimated an increase in
the tumor control probability (TCP) of 2–3 % with HT
compared with the faster 3D conformal RT due to the
lower dose rate of the latter, and an additional 2–3 %
compared with static-beam IMRT [5].
An additional argument against the longer treatment
times is based on economic and commercial consider-
ations [6, 7].
For all these reasons, in this study, it was decided to
speed up the HT system to treatment times comparable to
those obtained with RA (RA was used as benchmark as it
can be considered being more mainstream) and to quantify
the consequences on the quality of the treatment plan. This
acceleration is possible by varying 3 separate parameters in
the HT planning’s system: the beam width, the pitch and
the modulation factor. The beam width is the cranio-caudal
aperture of HTs fan beam multileaf collimator (MLC),
which we would call the length in a classical cone beam
collimator. One can choose between 1, 2.5 and 5 cm. With
increasing beam width also the craniocaudal gradient/
penumbra increases due to the typical characteristics of
the fan beam MLC of the actual TomoHD™ and older
systems [8, 9]. The recently released TomoEdge™
Dynamic Jaws of the TomoHDA™ system, referred to by
Sterzing et al. and Rong et al. as the ‘running-start-stop
delivery’, aims to resolve this issue by gradually adapting
the beam width at the craniocaudal outer ends of the
target volume [9–11]. The pitch is the distance covered
by the treatment couch relative to the beam width, dur-
ing one 360° rotation of the accelerator around the pa-
tient. As such, a pitch of 0.5 indicates that the
treatment couch advances 50 % of the beam width dur-
ing each rotation, which means that each point within
the tumor/patient can be irradiated/optimized during 2
full rotations. Finally, the modulation factor is the max-
imally accepted level of modulation. A larger beam
width, a larger pitch or a smaller modulation factor, can
each speed up the HT treatment.
In this planning study for head and neck cancer pa-
tients we plan to equal the treatment time parameter of
HT with the one obtained by RA. Both will be compared
with the standard HT plans in order to better under-
stand the dosimetric consequences of a faster treatment.
Finally, the impact of the new TomoEdge™ system will
be evaluated under fast conditions.
Methods
Only a brief summary is provided on patient characteris-
tics and treatment planning as these are based on a pre-
vious planning study and the reader is kindly referred to
that publication for more details [2].
Patient characteristics
For five patients with loco-regionally advanced oropha-
ryngeal cancer a contrast-enhanced reference CT scan
with 3 mm slice thickness was made in the treatment
position with a custom made immobilization mask. Pa-
tient characteristics are mentioned in Table 1. Primary
tumor volume and bilateral elective lymph node regions
and OARs were delineated.
Treatment planning
Volumes
The gross tumor volume (GTV), the clinical target
volume (CTV) and the nearby organs at risk (OARs)
were delineated on the same software platform for all
treatment plans (Pinnacle 8.0 m). The CTV69Gy (i.e.
the CTVtherapeutic) was defined as the GTV + 1 cm
(both for the primary tumor and for the regional
lymph node metastasis) respecting the anatomical
limitations of spread by bone, cartilages, ligaments,
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muscles and air. The rest of the CTV of both the pri-
mary tumor (tissue nearby at risk of direct spread) and
the bilateral elective lymph node areas (delineated ac-
cording to Gregoire et al. [12]) were united in the
CTV56Gy (i.e. the CTVprophylactic). The planning target
volumes (PTVs) 69 and 56 Gy were defined as the re-
spective CTVs plus a 3 mm margin with exclusion of
the skin. This skin, defined as a 3-mm thick layer
under the surface, was excluded from the PTV.1 The
PTV69Gy was created as a separated volume, i.e. was
not included in the PTV56Gy, to bypass HT’s overlap
priority system in which a single pixel can only repre-
sent one target volume.
The contoured OARs are listed in Table 2. The shoul-
der was delineated as the humeral head, including the
glenohumeral joint, up to the acromioclavicular joint.
The top of the lung is defined as the cranial part of the
lung above the aortic arc. OARs lying (almost) com-
pletely in the PTV were not contoured. A planning risk
volume (PRV) of 3 mm was created around the spinal
cord and around the brainstem.
Planning techniques
For each patient a treatment plan was made in the institu-
tion where a specific form of IMRT was in use. The
Tomotherapy plans were all made in the same institution
Table 1 Patient characteristics
Patient Location ICD-O 10 Classification
TNM/AJCC VI




1 Base of tongue R C01 T1N2aM0 IV A 2 & 3 R 104 483
2 Tonsil R C09 T2N2cM0 IV A 2 bilat & 3 R 233 610
3 Tonsil L C09 T3N2cM0 IV A bilat 1,2,3,4 380 955
4 Base of tongue R C01 T3N2cM0 IV A 1b R & 2 bilat 422 831
5 Tonsil L C09 T2N1M0 III 2 L 146 563
average 257 688
Abbreviations: Bilat bilateral, LN+ positive lymph node, R right, L left, PTVtotal PTVtherapeutic and PTVprophylactic together; PTV volumes reported in this table are
calculated by the Pinnacle treatment planning system




dose or D50 %














PRV Spinal cord D2 ≤50 Gy
PRV Brainstem ≤55 Gy D2 ≤59 Gy
Parotid gland contralateral ≤23 Gy Mean D, V27
Parotid gland ipsilateral ≤27 Gy Mean D, V27
Submandibular gland ≤39 Gy Mean D
Oral mucosa ≤27 Gy Mean D, V27
Mandible V60
Soft palate ≤27 Gy Mean D, V27
Constrictor muscles ≤55 Gy Mean D, V20
Cricopharyngeal muscle ≤55 Gy Mean D, V20
Base of tongue ≤55 Gy Mean D, V20
Larynx ≤40 Gy Mean D, V40
Esophagus superior ≤35 Gy Mean D, V35
Top of lung V20
Inner ear Mean D, V45
Abbreviations: PTV planning target volume, PRV planning risk volume, D dose, V volume, ALARA as low as reasonable achievable
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by the same physicist and finalized by the same radiation
oncologist. Techniques 1 and 2 used in this study are
identical to those used in a previous study, and serve as
comparators for techniques 3 and 4 [2].
1. A Helical Tomotherapy plan for a TomoHD™ system
was planned on the Tomotherapy planning software
version HD1.0 with a maximum of three dose
volume histogram (DVH) control points per volume.
A field width of 2.5 cm, a maximum modulation
factor of 2.8 and a pitch of 0.287 (to avoid the
thread effect [13]) were used. The dose distribution
for each beamlet was calculated with a convolution/
superposition algorithm. The optimization process
used the least mean square optimization method to
optimize the objective function.
2. A RapidArc treatment was planned for a Varian
CLINAC 2100 C/D upgraded with on board imaging
(OBI) and RapidArc. The plans were optimized
using the Progressive Resolution Optimizer (PRO)
8.6.15 and calculated with Anisotropic Analytical
Algorithm (AAA 8.6.15). Each plan consisted of two
6 MV 360° arcs, one clockwise (CW) and one
counter clockwise (CCW) of 177 control points
each. To avoid “tongue-and-groove” effects and to
improve target coverage and OAR protection,
collimator angles were set to 10° (CCW) and 80°
(CW) [14]. The collimator used was a 120 MLC for
a 40 by 40 cm field size (5 mm leaf width for the
central 20 cm, 10 mm leaf width for the outer
20 cm).
3. With the same Tomotherapy planning software
version HD1.0 a “Tomo Fast” (TF) plan was created.
By modifying the beam width from 2.5 to 5.0 cm,
elevating the pitch to 0.43 and lowering the
modulation factor from an initial 2.8 down to the
moment the required treatment time was reached,
plans with treatment times close to those of the RA
plans could be generated.
4. With the same technique as the TF plans, plans
were made for the recently released TomoEdge™
Dynamic Jaws system of the TomoHDA™ series
(TEF) [9–11]. With this new hardware it is possible
to gradually open the fan beam jaws at the
craniocaudal outer ends of target volume, avoiding
the typical larger craniocaudal penumbra of HT.
The dose distributions are calculated with the
VoLO™ algorithm using a convolution/superposition
algorithm.
Prescription and constraints
A simultaneous integrated boost technique was planned
in order to deliver in 32 fractions a dose of 69.12 Gy
(2.16 Gy / fraction) to the PTV69Gy and a dose of 56 Gy
(1.75 Gy / fraction) to the PTV56Gy, respecting the pre-
scription guidelines of the International Commission on
Radiation Units and Measurements (ICRU) report 83 [15].
The Near-Max dose (Dnear-max or D2%) to the PRV of
the spinal cord was limited to 50 Gy and a maximum of
59 Gy with 50 % of the volume (D50%) under 55 Gy was
tolerated to the PRV of the brainstem. The dose to all
OARs had to be kept as low as possible respecting the
prescription to the PTVs. An overview of the dose-
volume constraints for the PTVs and the different OARs
can be found in Table 2.
Data analysis and statistics
Reporting
For the PTVs the homogeneity index (HI, (D2%-D98%)/
D50%), the conformity index (CI, V95%Dprescribed(body)/
V95%Dprescribed(PTV)), the mean dose, the Dnear-min
(D98%) and the Dnear-max (D2%) were analyzed. The
V59.9Gy of the PTV56Gy (=107 % of the prescribed
dose) was calculated as an indication for the steepness
of the dose gradient towards the PTV69Gy. For 30
OARs the mean dose and specific critical doses and
volumes were analyzed. Organs overlapping with the
PTV in three patients or more were excluded from
this study. Finally the beam-on time, treatment time
and the number of monitor units were compared.
Analysis and statistics
Differences in the studied parameters between treat-
ment planning systems were analyzed using the general
linear model in the form of a repeated measures ana-
lysis of variance (ANOVA). By using a heterogeneous
covariance structure in the repeated measures model,
we allowed the variance to differ across systems. All
included variables were checked for normality. The p-
values of group comparisons were adjusted for multiple
testing using the false discovery rate (FDR) correction.
All hypotheses were tested non-directionally with a p-
value of less than 0.05 considered to be significant. All
analyses were performed using SAS 9.2 (SAS Institute
Inc., Cary, NC).
Results
For HT and RA the results of our previous planning study
were used [2]. The modulation factor for TF and TEF was
lowered from 2.8 to a mean of 2.30 (range 2.0–2.6) and
2.36 (range 2.0–2.8), respectively.
PTVs
An overview of the mean results and corresponding
p-values for PTV69Gy and PTV56Gy is given in Table 3,
the corresponding dose volume histograms can be
found in Fig. 1.
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PTV69Gy: D2% and D50% ICRU 83 guidelines were well
respected by all techniques, the D98% guideline was
respected by HT, TF and TEF. This resulted in a statisti-
cally significant lower homogeneity index (mean HI .06,
.07 and .08 for HT, TF and TEF, respectively) compared
to RA (mean HI .10). The mean Conformity Index was
best for RA (1.10), remained the same for TF compared
to HT (1.33), but was clearly worse for TEF (1.49).
PTV56Gy: the D50% guideline was less well respected
by RA, D98% was only respected by HT and D2% by none.
A statistically significant lowest homogeneity index was
obtained by RA (.19), and HT (.24) did better than TF
and TEF (.26 and .28, respectively). The Conformity
index PTV56Gy was worst for TEF.
OARs
For 26 organs at risk, an extensive list of mean values
and organ specific critical doses and volumes is given
in Table 4. Mean doses to the parotid glands, for
example, were comparable for RA, TF and TEF:
25.62 Gy, 25.34 Gy and 23.09 for the contralateral
and 32.02 Gy, 31.96 Gy and 30.01 for the ipsilateral
gland, respectively. When comparing the fast tech-
niques, spinal cord, cricopharyngeal muscle and cra-
nial part of the esophagus received a lower mean
dose when planned with TF or TEF, the supraglottic
larynx when planned with RA.
At the same time, these fast techniques lose the dosi-
metric advantage of HT. The composite dose volume
Table 3 Mean values of PTVs for the different planning techniques
Abbreviations: PTV planning target volume
The left side of the table gives the mean values of the PTVs. the right part of the table indicates the statistically significant differences (Repeated Measures
ANOVA) between the five techniques. each with its own colour highlighting the technique doing best in the comparison: red = Helical TomoHD; yellow = RapidArc
VMAT; blue = TomoHD Fast; green = TomoEdge Fast. For HT and RA the results of our previous planning study were used [2]
Fig. 1 Composite dose volume histograms of mean PTV69Gy and mean PTV56Gy, with averaged data from the five plans
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histograms pooled from the five plans of the OARs and
the total body can be found in Fig. 2.
Monitor units, beam-on time and treatment time (see
Table 3)
The mean number of monitor units was statistically
lower for RA (415) compared to TF (2384) and TEF
(2436), both requiring half the MU of HT (5052). Mean
beam-on time was 2.5 min for RA, 2.9 min for TF and
TEF, and 5.9 min for HT. Treatment times (excluding
patient set-up) were 3.05 min for RA and remained the
same as the beam on time for the 3 helical tomotherapy
techniques.
Discussion
Typically, all rotational IMRT systems are performing
quite well with the faster techniques (RA, TF and TEF)
keeping the target volume coverage acceptable, but com-
promising the sparing of organs at risk.
Globally, the target volume coverage is the best with
standard HT, yet acceptable results are obtained with
the faster techniques. Especially the difference with TF is
minimal in this study. TF and TEF score better than RA
for the PTV69Gy but worse for the PTV56Gy. This can be
explained by the placing of the dose gradient between
both dose levels which, in this study, is placed in the
elective/prophylactic dose zone in the Tomotherapy
techniques and in the high dose zone in RA. It remains
unclear whether the place of the dose gradient is inher-
ent to the planning system or whether it is planner/insti-
tution driven. The clinical relevance of the observed
differences in PTV coverage can be argued. The moder-
ate CI for standard HT, especially in comparison with
RA, is explained by the high D98 % which pushes a big-
ger part of the D95 % outside the PTV. This implies that
we might have made these plans to homogeneous,
maybe at the expense of an even better sparing of the
OARs.
For most of the OARs, TF and TEF lose the standard
HT’s dosimetric advantage over RA and thus also the
probable clinical benefit in parotid gland sparing, swal-
lowing function preservation and easier re-irradiation as
discussed in our previous article [2]. Differences in OAR
sparing between the three faster techniques are very
small with almost similar mean dose to both parotids
and the oral mucosa. Furthermore, some OARs are
doing better with TF/TEF (Spinal cord, cricopharyngeal
muscle and cranial part of the esophagus), while others
(e.g. supraglottic larynx) are doing better when planned
with RA. For the OARs at the cranio-caudal edges of the
PTV (e.g. eyes, ears, lung tops, brain and shoulders), TF
is doing worse than RA due to the craniocaudal
Table 4 Critical doses and volumes of the different organs at risk for the different planning techniques
Abbreviations: PRV planning risk volume, PTV planning target volume, SE standard error; high and low: was used in symmetrical organs where ‘ipsi- and
contralateral’ was not appropriate; NA not analysed because of the low number of parameters
The left side of the table gives the mean values of the OARs. the right part of the table indicates the statistically significant differences (Repeated Measures
ANOVA) between the five techniques. each with its own colour highlighting the technique doing best in the comparison: red = Helical TomoHD; yellow = RapidArc
VMAT; blue = TomoHD Fast; green = TomoEdge Fast. For HT and RA the results of our previous planning study were used [2]
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Fig. 2 Composite dose volume histograms of mean values of organs at risk and body, with averaged data from the five plans
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penumbra caused by the open/close fan beam. With
exception of the ears, this problem is not present in the
TEF planning, as the TomoEdge™ Dynamic Jaws of the
TomoHDATM series makes it possible to gradually adapt
the beam width at the craniocaudal edges of the target
volume, reducing the cranio-caudal penumbra [9–11].
This edge effect also translates into a 20 % higher inte-
gral dose for TF compared to standard HT, while TEF
recuperates a large part of this disadvantage (only 6 %
higher integral dose). This corresponds to the findings of
Sterzing et al. in a preclinical planningstudy on 10 naso-
pharyngeal cancer cases observing a 12.5 % increase and
a 5.7 % decrease of the integral dose, respectively [9].
However, for TEF the same group recently reported a
3.1 % increase in integral dose in a mixed tumor popu-
lation in a clinical setting [11]. We found TEF to have
an inferior CI compared to TF, which is rather surpris-
ing. A similar observation has been made in the studies
of Sterzing et al. and of Rong et al. [9, 10]. This can
possibly be explained by the fact that the VoLO algo-
rithm of the TomoEdge™ system, in order to speed up
calculation time, skips the time consuming beamlet
calculation which makes use of the Collapsed Cone
Convolution Superposition (CCCS) approach. It imme-
diately starts with the optimization process using a new
Fluence Convolution Broad Beam (FCBB) dose calcula-
tion in combination with a full scatter dose calculation
every ten iterations. This different approach can prob-
ably result in minor differences in the calculated dose
distribution [16].
However, the study of Sterzing et al. was performed
on a prototype which has afterwards been recognized
not to be suitable for clinical use. The only other studies
so far that report on the clinical released TomoEdge
system are the studies by Rong and colleagues and the
recent study of Katayama et al. [10, 11]. The first re-
ported on 20 patient cases of which four head and neck
cancer (HNC) cases; the latter on 45 patients of which
16 HNC cases. However, most of these HNC cases were
not very challenging, originated from different head and
neck sites, had different dose prescriptions and only
very few OARs were reported on. The main focus of
both studies was a safe faster treatment delivery by the
TomoEdge system but they failed to uniformly quantify
the dosimetrical impact on the OARs. In our study, on
the other hand, we found a clear dosimetrical impact of
the faster delivery in comparison to the standard HT
plan.
A faster treatment delivery might be beneficial for
intrafractional motion and for the patient who might
stay for a shorter period of time under the
immobilization mask. However, the importance of re-
ducing treatment times from 6 to about 3 min can be
questioned given the overall in-room time that is
much longer due to the daily repositioning of the pa-
tient and the image guidance. Nevertheless, with time
slots of 20 min, a gain of 3 min per patient (=15 %)
with the faster techniques results in an extra four pa-
tients that can benefit of an IMRT technique during
the same 8 h working day compared to standard HT.
This might not be an issue in academic centers with
enough machine time, but it might be an issue in
smaller hospitals.
Moreover, we already pointed out that a faster treat-
ment delivery possibly is beneficial by avoiding cell kill
repair and how HT therefore might result in an in-
crease in the tumor control probability [3, 5]. As stand-
ard HT is already treating an individual point/voxel
much faster than other techniques (42 s at maximum
gantry speed for a pitch of .287), TF and TEF further
decrease this time to minimally 28 s for a pitch of .43
used with the 5 cm beam width. Hence, a further in-
crease in the tumor control probability might be ex-
pected. However, we realize that this hypothesis is
merely speculative.
We also realize that the statistical power of a sample
size of only five patients (each of them planned with the
four planning systems) has its limitations. Since normal-
ity of the results of such a small sample cannot be
proven, non-parametric tests would be the first choice.
However, with Wilcoxon signed rank tests it is theoretic-
ally impossible to get a p-value of less than .05 in such a
small group. Visual inspection of the data by means of
boxplots and qq-plots showed large differences between
the different techniques and no major deviations from
normality. Therefore repeated measures ANOVA models
were performed. When differences are sufficiently large
and the variability within each system is small, as is the
case in the present study, repeated measures ANOVA
has the power to pick up these differences. However, the
authors realize that smaller differences may be missed as
non-significant results may be due to the low number of
patients, and thus not necessarily implement that the
different systems are equal for these parameters. An-
other possible bias encountered in the present study is
the fact that the RA and HT plans have been planned by
different institutes and thus different planners. This is
beneficial in that each technique has been planned by
the most experienced planner, but it might introduce
uncertainty whether the observed differences are not
due to the planner rather than being technique specific.
This is true for the comparison between RA and HT but
is invalid for the comparison among the three HT tech-
niques as they all have been planned in the same way by
the same planners. As the impact of treatment time on
the HT plan quality was the main goal of our study and
as the RA plans were only referred to as a more
mainstream benchmark, we are quite confident that
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differences in planner introduced only minor influences
to the endpoints of our study.
Finally, this study was limited to two situations, a stand-
ard plan and a fast plan, but an infinite number of combi-
nations of pitch, width and modulation factor, each with its
specific characteristics can be explored. In order to guide
the planner’s choice for the case specific best parameters, a
HT specific Pareto front has been developed which has
been subject of another publication [17].
Conclusion
HT can be speeded up to about half the original
treatment time, obviously at the cost of less sparing
of the OARs. Lately, the focus in radiotherapy has
been shifted towards speed of treatment delivery
(largely driven by economical and commercial inter-
ests). With this paper we hope to show that speed is
an artificial argument inferior to quality. The choice
is not technology dependent, rather a decision made
by the user to find the correct balance.
Endnotes
1This has been described in a previous study where it
has been done in order to avoid 1) optimization prob-
lems with the static beam IMRT systems due to their
physical inability to create proper dose in the build-up
zone, in this case the skin; and 2) overdose to the skin
created by the rotational IMRT systems [2].
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